NCT01419691

Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: University of Kansas Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).

Conditions

• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma
• Leukemia, Prolymphocytic

Interventions

Type	Name	Description
DRUG	auranofin	6 mg twice a day for a total of 12 mg total daily dose

Timeline

• Start date: 2011-09-01
• Primary completion: 2015-09-01
• Completion: 2015-09-01
• First posted: 2011-08-18
• Last updated: 2016-01-18

Locations

1 site across 1 country: United States